Biotechnology
HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell
KEY POINTS * First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple myeloma * Patient was monitored after initial dose to assess response and side-effects, with the treatment seen as well tolerated, an...
2026-08-26 08:00
1355
Metabolon Completes Landmark Global Health Pilot Advancing Women's and Infant Health
Innovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations from low- and middle-income countries MORRISVILLE, N.C., Aug. 25, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics solut...
2026-08-25 21:00
1138
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
EAST RUTHERFORD, N.J., Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Admini...
2026-08-25 18:00
1031
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-25 08:30
1906
ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation
HONG KONG, Aug. 24, 2026 /PRNewswire/ -- The Hong Kong Applied Science and Technology Research Institute (ASTRI) and Saint Francis University (SFU) have signed a Memorandum of Understanding (MoU) to establish a strategic partnership focused on advancing research and development in AI-enabled biom...
2026-08-24 15:40
2360
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-24 09:00
3199
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of ...
2026-08-24 08:00
1785
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB 3.5882 billion, a 27.3% ...
2026-08-21 21:50
18790
3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company rea...
2026-08-21 15:39
5800
Sunshine Guojian Releases 2026 Interim Report:
Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the f...
2026-08-21 08:00
4221
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution Conference Cal...
2026-08-21 07:10
4346
Angel Yeast's AHH Packaging Design Recognized with Red Dot Award
SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Angel Nutritech, a professional yeast
biotechnology subsidiary underAngel Yeast
2026-08-21 00:06
10093
ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou
ICORE launched; nine companies joined as founding members HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ -- On August 18, the International Society of Organoid Research (ISoOR) held its 2026 Organoid Clinical TransformationSummit in Hangzhou. Under the theme "From Biological Models to Credible Evid...
2026-08-20 13:08
1279
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance[1]: Double-digit revenue growth and gross margin imp...
2026-08-20 08:02
3151
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer
oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 NATICK, Mass. and TOKYO, Aug. 20, 2026 /PRNewswire/ -- Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medie...
2026-08-20 06:00
2312
XtalPi Holdings Announces 2026 Interim Results
SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ -- Financial Highlights: * In the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the correspondin...
2026-08-19 21:19
2965
Sisram Medical Delivers Solid 2026 Interim Results
Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy...
2026-08-19 20:00
2663
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Scie...
2026-08-19 19:45
2724
Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, dr...
2026-08-19 14:48
1089
Everest Medicines Announces Interim Results for First Half of 2026
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first hal...
2026-08-19 11:39
2729
Week's Top Stories
Most Reposted
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 293 media titles]
2026-09-22 18:37
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 281 media titles]
2026-09-23 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 275 media titles]
2026-09-25 14:45
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13152
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
11871
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
10826
